- Home
- NEUP vs KPRX Comparison
NEUP vs KPRX Comparison
Compare NEUP & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEUP
- KPRX
- Stock Information
- Founded
- NEUP 1996
- KPRX 1998
- Country
- NEUP United States
- KPRX United States
- Employees
- NEUP N/A
- KPRX N/A
- Industry
- NEUP
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- NEUP
- KPRX Health Care
- Exchange
- NEUP Nasdaq
- KPRX Nasdaq
- Market Cap
- NEUP 9.3M
- KPRX 8.3M
- IPO Year
- NEUP N/A
- KPRX N/A
- Fundamental
- Price
- NEUP $5.04
- KPRX $3.20
- Analyst Decision
- NEUP Strong Buy
- KPRX Strong Buy
- Analyst Count
- NEUP 1
- KPRX 1
- Target Price
- NEUP $21.00
- KPRX $10.00
- AVG Volume (30 Days)
- NEUP 21.4K
- KPRX 9.6K
- Earning Date
- NEUP 05-15-2025
- KPRX 05-09-2025
- Dividend Yield
- NEUP N/A
- KPRX N/A
- EPS Growth
- NEUP N/A
- KPRX N/A
- EPS
- NEUP N/A
- KPRX 0.87
- Revenue
- NEUP $662,715.00
- KPRX $16,020,000.00
- Revenue This Year
- NEUP N/A
- KPRX N/A
- Revenue Next Year
- NEUP N/A
- KPRX N/A
- P/E Ratio
- NEUP N/A
- KPRX $3.68
- Revenue Growth
- NEUP N/A
- KPRX N/A
- 52 Week Low
- NEUP $2.12
- KPRX $2.51
- 52 Week High
- NEUP $15.24
- KPRX $5.55
- Technical
- Relative Strength Index (RSI)
- NEUP N/A
- KPRX 62.37
- Support Level
- NEUP N/A
- KPRX $3.06
- Resistance Level
- NEUP N/A
- KPRX $3.29
- Average True Range (ATR)
- NEUP 0.00
- KPRX 0.20
- MACD
- NEUP 0.00
- KPRX 0.08
- Stochastic Oscillator
- NEUP 0.00
- KPRX 88.46
About NEUP Neuphoria Therapeutics Inc. Common Stock
Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.